| Cat. No. |
Product Name |
Information |
| PC-44040 |
NVP-BSK805 dihydrochloride
JAK2 inhibitor
|
NVP-BSK805 dihydrochloride is a potent, selective and ATP-competitive inhibitor of JAK2 (V617F) and wt JAK2 (IC50=0.5 nM). |
| PC-44039 |
NVP-BSK805
JAK2 inhibitor
|
NVP-BSK805 is a potent, selective and ATP-competitive inhibitor of JAK2 (V617F) and wt JAK2 (IC50=0.5 nM). |
| PC-45575 |
CHZ-868
JAK2 inhibitor
|
CHZ-868 (CHZ868) is a potent type II JAK2 inhibitor, inhibits the proliferation of SET2 JAK2 V617F cells (GI50=59 nM). |
| PC-45448 |
Filgotinib
JAK1/2 inhibitor
|
Filgotinib (GLPG 0634) is a potent JAK1/JAK2 inhibitor with IC50 of 10 nM/28 nM in biochemical assays, less potent for JAK3 and TYK2. |
| PC-44289 |
BMS-911543
JAK2 inhibitor
|
BMS-911543 is a potent and selective small-molecule inhibitor of JAK2 with IC50 of 1.1 nM. |
| PC-42753 |
CYT387 mesylate
JAK1/2 inhibitor
|
Momelotinib mesylate (CYT387 mesylate) is a potent and selective JAK1/JAK2 inhibitor with IC50 of 11/18 nM. |
| PC-42752 |
CYT387 sulfate
JAK1/2 inhibitor
|
Momelotinib (CYT387) sulfate is a potent and selective JAK1/JAK2 inhibitor with IC50 of 11/18 nM. |
| PC-42751 |
CYT387
JAK1/2 inhibitor
|
Momelotinib (CYT387) is a potent and selective JAK1/JAK2 inhibitor with IC50 of 11/18 nM. |
| PC-45123 |
Itacitinib
JAK1 inhibitor
|
Itacitinib (INCB-039110) is a potent and selective, orally bioactive JAK1 inhibitor with IC50 of 2 nM, shows >20 fold and >200 fold selectivity over JAK2 and JAK3 respectively. |
| PC-24191 |
Tofacitinib etocomil
JAK inhibitor
|
Tofacitinib etocomil (MH004) is a is a topical product containing a JAK inhibitor tofacitinib, shows extensive target inhibition in local skin tissues without systemic toxicities, has potential for multiple dermatologic autoimmune diseases. |
| PC-24170 |
Plodicitinib
JAK3/TEC kinase inhibitor
|
Plodicitinib is a highly potent, dual inhibitor of JAK3 kinase and BTK kinase with IC50 of 0.3 nM and 2.4 nM, respectively. |
| PC-24155 |
Milpecitinib
JAK inhibitor
|
Milpecitinib is potent, selective Janus tyrosine kinase (JAK) inhibitor. |
